Product Details
Place of Origin: China
Brand Name: Sunshine
Certification: ISO,COA
Model Number: 57773-63-4
Payment & Shipping Terms
Minimum Order Quantity: Negotiation
Price: Negotiation
Packaging Details: Aluminum Foil Bag, Drum
Delivery Time: 7-15DAY
Payment Terms: L/C,D/A,D/P,Western Union,T/T,MoneyGram
Supply Ability: G,KG,TON
CAS NO:: |
57773-63-4 |
Appearance:: |
Powder |
Molecular Formula:: |
C64H82N18O13 |
Molecular Weight:: |
1311.45000 |
EINECS NO:: |
637-328-4 |
MDL NO:: |
MFCD00167541 |
CAS NO:: |
57773-63-4 |
Appearance:: |
Powder |
Molecular Formula:: |
C64H82N18O13 |
Molecular Weight:: |
1311.45000 |
EINECS NO:: |
637-328-4 |
MDL NO:: |
MFCD00167541 |
Product Description:
Product Name: Triptorelin CAS NO: 57773-63-4
Synonyms:
PGLU-HIS-TRP-SER-TYR-D-TRP-LEU-ARG-PRO-GLY-NH2;
PYROGLU-HIS-TRP-SER-TYR-D-TRP-LEU-ARG-PRO-GLY NH2;
TRIPTORELIN AMIDE;
Chemical & Physical Properties:
Appearance: Powder
Assay :≥99.00%
Density: 1.52 g/cm3
Storage Condition: -20℃
Safety Information:
Safety Statements: S53-22-36/37/39-45
WGK Germany: 3
Risk Statement: R60
Hazard Code: T
Triptorelin, a decapeptide (pGlu-His-Trp-Ser-Tyr-D-Trp-Leu-Arg-Pro-Gly-NH2), is a gonadotropin-releasing hormone agonist (GnRH agonist) used as the acetate or pamoate salts. By causing constant stimulation of the pituitary, it decreases pituitary secretion of gonadotropins luteinizing hormone (LH) and follicle stimulating hormone (FSH). Like other GnRH agonists, triptorelin may be used in the treatment of hormone-responsive cancers such as prostate cancer or breast cancer, precocious puberty, e-strogen-dependent conditions (such as endometriosis or uterine fibroids), and in assisted reproduction. It is also used as therapy in cases of gender dysphoria. Triptorelin is marketed under the brand names Decapeptyl (Ipsen) and Diphereline and Gonapeptyl (Ferring Pharmaceuticals). In the United States, it is sold by Watson Pharmaceuticals as Trelstar. In Iran Triptorelin is marketed under the brand name Variopeptyl (Varian Darou Pajooh).
During the treatment of prostate cancer it does cause a surge of t-estosterone (an initial uplevel of t-estosterone levels), known as a flare effect. In men a reduction of serum t-estosterone levels into the range normally seen after surgical castration occurs approximately two to four weeks after initiation of therapy. In contrast, gonadotropin-releasing hormone antagonists do not cause a surge, but a sudden reduction of t-estosterone levels. Systematic IUPAC Name: [d-Trp6]GnRH.
If you are interested in our products or have any questions, please feel free to contact us!
Products under patent are offered for R & D purpose only. However, the final responsibility lies exclusively with the buyer.